Clinical trials: Drug Interaction Potentiation
Drug Interaction Potentiation
A Drug-Drug Interaction Study of Warfarin and PA21
The purpose of this study is to determine if Warfarin is affected by PA21.
- Trial name
- NCT01477424
- Testing
- PA21, Warfarin
- Where
- United States
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Vifor Pharma
Drug Interaction Potentiation
A Drug-Drug Interaction Study of N91115 +/- Rifampin in Healthy Adult Subjects
The present study is designed to assess the effects of Rifampin on the pharmacokinetics of N91115 in healthy subjects.
- Trial name
- NCT02500667
- Testing
- N91115, Rifampin
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Nivalis Therapeutics, Inc.
Drug Interaction Potentiation, Pharmacokinetics
Study to Evaluate the Effect of Rabeprazole on the Pharmacokinetics of Vadadustat
This is a Phase 1, fixed sequence, open-label study to evaluate the effect of multiple oral doses of rabeprazole on the pharmacokinetics of a single dose of vadadustat 300 mg in healthy male and female subjects.
- Trial name
- NCT03789032
- Testing
- Vadadustat, Rabeprazole
- Where
- Canada
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Akebia Therapeutics
Drug Interaction Potentiation
Study to Evaluate Pharmacokinetic Drug Interactions and Safety of Ilaprazole and Aceclofenac
This study evaluate the pharmacokinetic drug interactions and safety after co-administration of ilaprazole and Aceclofenac in healthy adults.
- Trial name
- NCT05558150
- Testing
- Ilaprazole, Aceclofenac
- Where
- South Korea
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Il-Yang Pharm. Co., Ltd.
Healthy
A Drug-Drug Interaction Study of Omeprazole and PA21
The purpose of this study is to determine if Omeprazole is affected by PA21.
- Trial name
- NCT01452906
- Testing
- PA21 and Omeprazole with food, No PA21; Omeprazole with food, PA21 with food, Omeprazole 2hrs later
- Where
- United States
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Vifor Pharma
Adverse Drug Events, Adverse Drug Reactions
YouScript IMPACT Registry
This multicenter observational study aims to investigate the benefits of providing pharmacogenetic testing with the YouScript Personalized Prescribing System which includes a clinical decision support tool and individualized…
- Conditions
- Adverse Drug Events, Adverse Drug Reactions, Drug Interaction Potentiation, Drug Metabolism, Poor, CYP2D6-RELATED
- Trial name
- IMPACT (NCT02191358)
- Where
- 7 sites in United States
- Volunteers
- 800 people
- Sponsor
- Genelex Corporation
Pharmacokinetics, Inhibition Enzyme
Pharmacokinetic Interaction Between Trospium With an Inhibitor of OCT1 and of P-gp in Subjects Genotyped for OCT1
The purpose of the study is: to determine absolute bioavailability, input rates, distribution volume, renal and intestinal excretion of trospium in subjects with wild-type of SLC22A1 rs72552763 and rs12208357 and in subjects with…
- Conditions
- Pharmacokinetics, Inhibition Enzyme, Drug Interaction Potentiation
- Trial name
- NCT03011463
- Testing
- intravenous infusion of 2 mg trospium chloride, oral administration of 30 mg trospium chloride, oral administration of 300 mg ranitidine
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Dr. R. Pfleger Chemische Fabrik GmbH
Drug Interaction Potentiation
Drug-Drug Interaction Study of Vadadustat With Cyclosporine, Probenecid and Rifampin
This is a Phase 1, two-part, open-label study to evaluate the interaction of cyclosporine, probenecid, and rifampin as perpetrators with vadadustat (victim) in healthy male and female subjects.
- Trial name
- NCT03801746
- Testing
- vadadustat, Rifampin, Probenecid
- Where
- Canada
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Akebia Therapeutics
Drug Interaction Potentiation
Study to Evaluate Pharmacokinetic Drug Interactions and Safety of Clarithromycin, Amoxicillin and Ilaprazole
This study evaluate the pharmacokinetic drug interaction in Ilaprazole, Clarithromycin, Amoxicillin.
- Trial name
- DDI (NCT02998437)
- Testing
- Ilaprazole 10mg, Clarithromycin 500mg, Amoxicillin 500 Mg
- Where
- South Korea
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Il-Yang Pharm. Co., Ltd.
Drug Interaction Potentiation
Study to Evaluate Pharmacokinetic Drug Interactions and Safety of Naproxen, Aceclofenac, Celecoxib and Ilaprazole
This study evaluate the pharmacokinetic drug interactions and safety after co-administration of ilaprazole and NSAID in healthy adults.
- Trial name
- NCT05237297
- Testing
- Ilaprazole, Naproxen, Aceclofenac
- Where
- South Korea
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Il-Yang Pharm. Co., Ltd.
Healthy
A Drug-Drug Interaction Study of Furosemide and PA21
The purpose of this study is to determine if Furosemide is affected by PA21.
- Trial name
- NCT01438359
- Testing
- PA21 and Furosemide with food, No PA21; Furosemide with food, PA21 with food and Furosemide 2hrs later
- Where
- United States
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Vifor Pharma
Drug Interaction Potentiation
Drug-Drug Interaction Study of Vadadustat With Digoxin, Adefovir and Furosemide
This is a Phase 1, open-label, 3-arm, fixed sequence, study to evaluate vadadustat as a perpetrator of drug-drug interactions (DDIs) with digoxin, adefovir and furosemide in healthy male and female subjects.
- Trial name
- NCT03801759
- Testing
- Vadadustat, Furosemide, Adefovir
- Where
- Canada
- Volunteers
- 62 people, healthy volunteers welcome
- Sponsor
- Akebia Therapeutics
Drug Interaction Potentiation
Pharmacokinetic Interaction Study of Dapoxetine 30mg and Mirodenafil 100mg
Healthy male volunteers were administered alone and in combination with dapoxetine 30mg mirodenafil 100mg for three times, respectively and the pharmacokinetic interaction was compared between the two drugs.
- Trial name
- NCT02485041
- Testing
- Dapoxetine 30mg, Mirodenafil 100mg
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- SK Chemicals Co., Ltd.
Drug Interaction Potentiation
Open-label, Single Center, Non-randomized, Fixed Sequence Phase 1 Drug-drug Interaction Study With LEO 32731 and Midazolam
This is a single center, non-randomized, open-label, fixed sequence study to investigate the effect of multiple oral dosing of LEO 32731 (up-titrated), on CYP3A activity in healthy male subjects using midazolam as a probe CYP3A…
- Trial name
- NCT03126578
- Testing
- LEO 32731, Midazolam
- Where
- Germany
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- LEO Pharma
Drug Interaction Potentiation
A Fixed-Sequence, Drug-Drug Interaction Study Between Multiple Oral Doses of Inarigivir Soproxil and a Single Oral Dose of Midazolam in Healthy Subjects
This is a single center, open-label, fixed sequence study to investigate the effect of multiple oral dosing of Inarigivir Soproxil and a single oral dose of Midazolam in Healthy Subjects
- Trial name
- NCT03493698
- Testing
- Midazolam, Inarigivir
- Where
- Netherlands
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- F-star Therapeutics, Inc.
Drug Interaction Potentiation
A Drug-Drug Interaction Study of Digoxin and PA21
The purpose of this study is to determine if Digoxin is affected by PA21.
- Trial name
- NCT01477411
- Testing
- PA21, Digoxin
- Where
- United States
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Vifor Pharma
Drug Interaction Potentiation, Healthy
Mifepristone Drug-Drug Interaction Study With CYP3A Inhibitor
This is a Phase 1, single-center, fixed-sequence, open label, drug-drug interaction study of the effect of multiple daily doses of oral itraconazole 200 mg, a strong inhibitor of CYP3A, given with mifepristone 900 mg QD, in…
- Trial name
- NCT03259542
- Testing
- Mifepristone 300 MG, Itraconazole 100 MG
- Where
- United States
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Corcept Therapeutics
Adverse Drug Events, Adverse Drug Reactions
Pharmacogenetic Testing Among Home Health Patients
Patients meeting eligibility criteria will be randomized into two groups, one receiving pharmacogenetic testing and the other not receiving pharmacogenetic testing.
- Conditions
- Adverse Drug Events, Adverse Drug Reactions, Drug Interaction Potentiation, Drug Metabolism, Poor, CYP2D6-RELATED
- Trial name
- NCT02378220
- Testing
- Pharmacogenetic testing
- Where
- United States
- Volunteers
- 110 people
- Sponsor
- Genelex Corporation
Drug Interaction Potentiation
Drug-Drug Interaction Study of Vadadustat With Rosuvastatin, Sulfasalazine, Pravastatin, Atorvastatin and Simvastatin
This is a Phase 1, three-part, open-label study to evaluate vadadustat as a perpetrator in drug-drug interactions with rosuvastatin, sulfasalazine, pravastatin, atorvastatin and simvastatin in healthy male and female subjects.
- Trial name
- NCT03801733
- Testing
- Vadadustat, Simvastatin, Rosuvastatin
- Where
- Canada
- Volunteers
- 134 people, healthy volunteers welcome
- Sponsor
- Akebia Therapeutics
Drug Interaction Potentiation
A Drug-Drug Interaction Study of Losartan and PA21
The purpose of this study is to determine if Losartan potassium is affected by PA21.
- Trial name
- NCT01324752
- Testing
- PA21 and Losartan with Food, No PA21; Losartan with food, PA21 with food and Losartan 2 hours later
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Vifor Pharma